Coronavirus: Vaccination
The question
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of establishing a national referral pathway or specialist hub for people who cannot receive mRNA vaccines to ensure equitable access to appropriate COVID-19 vaccinations.
Answered by Ashley Dalton
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
- adults aged 75 years old and over;
- residents in care homes for older adults; and
- individuals aged six months old and over who are immunosuppressed.
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →